IPOs - Page 1 | TalkMarkets
All Posts > Content under IPOs
1 to 16 of 906 Posts
1 2 3 ... 57
Legacy Housing Corporation Is A Good Old Fashioned Business
Article By: IPO Candy
Monday, December 10, 2018 1:45 PM EST
Legacy is small and has exercised excellent control of their own destiny. From a smaller base, Legacy has an easier time growing and they have been very effective at generating returns on capital.
In this article: LEGH Also: SUI, ELS, UMH, SKY, CVCO, BRK-A
Read
Avalara An Attractive Short Ahead Of Lockup Expiration
Article By: Don Dion
Monday, December 10, 2018 12:08 AM EST
The 180-day lockup period for Avalara Inc. (AVLR) ends on December 12, 2018. When this period ends, company's pre-IPO shareholders may opt to sell large blocks of currently-restricted shares for the first time.
In this article: AVLR
Read
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By: ChinaBio® Today
Saturday, December 8, 2018 4:21 PM EST
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
In this article: RVNC, VBIV, CASI, SPPI
Read
MOGU Is Meh At Best
Article By: IPO Candy
Wednesday, December 5, 2018 2:09 PM EST
MOGU is a deal that feels a little desperate even with bulge bracket bankers like Morgan Stanley and Credit Suisse
In this article: MOGU Also: JD, ZU, QRTEA
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: CStone Pharma, A Suzhou Oncology Company, Files For Hong Kong IPO
Article By: ChinaBio® Today
Saturday, November 17, 2018 5:26 PM EST
Suzhou's CStone Pharma has filed for a Hong Kong IPO. Founded in 2015, CStone has quickly built a portfolio of 14 oncology candidates.
In this article: A, CUE
Read
Week In Review: BioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million
Article By: ChinaBio® Today
Saturday, November 10, 2018 4:08 PM EST
French in vitro diagnostics company, bioMérieux (Paris: BIM), acquired a majority stake in Suzhou Hybiome Biomedical Engineering for $114 million. Hybiome specializes in automated immunoassay tests.
In this article: ASND, EYPT
Read
Pluralsight Could Falter When Lockup Expires
Article By: Don Dion
Thursday, November 8, 2018 5:20 AM EST
The 180-day lockup period for Pluralsight LLC (PS) ends on November 13, 2018. This date marks the point when the company's pre-IPO shareholders and insiders may sell large blocks of currently restricted shares in the secondary market.
In this article: PS Also: CSOD
Read
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Article By: ChinaBio® Today
Saturday, October 27, 2018 5:08 PM EST
Innovent Biologics has priced its Hong Kong IPO to raise $421 million. The successful IPO shows investors are still interested in young China biopharmas. he IPO values Innovent at $2 billion; its shares will begin trading on October 31.
In this article: CASI, ZLAB
Read
Money Is A YETI 110 Iced Down With Some Silver Bullets
Article By: IPO Candy
Tuesday, October 23, 2018 3:21 PM EST
YETI Holdings will be coming public this week (prices Wednesday) and promises to be one of the next public niche consumer brands like Duluth Holdings and Canada Goose.
In this article: YETI Also: DLTH, GOOS, ESTC
Read
Funding Secured
Article By: Ben Hunt
Sunday, October 21, 2018 1:35 PM EST
Can you imagine if Tesla were moving forward with the Saudi sovereign wealth fund in a take-private transaction? Can you imagine the uproar over doing this sort of major deal with the Saudis after the Khashoggi murder? Well, no need to imagine.
Read
Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation
Article By: ChinaBio® Today
Saturday, October 20, 2018 4:16 PM EST
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.
In this article: LLY, APDN, CGIX, HCM
Read
Weaponized Analytics?
Article By: IPO Candy
Saturday, October 13, 2018 1:05 PM EST
Anaplan has taken $300M to build a product sophisticated enough to handle the kind of large and complex planning requirements of enterprise customers in the high end of the Global 2000.
In this article: PLAN Also: WDAY, ESTC, DATA
Read
Evaluating Spotify (SPOT) Stock Six Months After IPO
Article By: Zacks Investment Research
Thursday, October 11, 2018 10:30 PM EST
Spotify went public at a time when subscription-based streaming was mainstream - and maybe that's the problem.
In this article: AAPL, SPOT Also: DIS, T, VZ, AMZN, NFLX, GOOGL
Read
Pivotal Could Shift Lower When Lockup Expires
Article By: Don Dion
Monday, October 8, 2018 2:40 PM EST
When PVTL's 180-day lockup period expires on October 17th, pre-IPO shareholders and company insiders will be able to sell large blocks of currently restricted shares for the first time.
In this article: PVTL
Read
Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
Article By: ChinaBio® Today
Saturday, October 6, 2018 5:57 PM EST
Shanghai Fosun Pharma announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary The company was established to develop mAb biosimilar drugs, bio-betters and novel mAbs.
In this article: GILD, CBMG
Read
1 to 16 of 906 Posts
1 2 3 ... 57